• BD Medical (Oxford, UK), a segment of BD (Becton, Dickinson and Company), reported the UK launch of the latest BD Nexiva Closed IV Catheter System designed to reduce healthcare workers' risk of needlestick injuries and minimize exposure to blood. The system includes the BD Q-Syte Luer Access Split Septum to help reduce catheter-related bloodstream infections. The new version of the BD Nexiva system features new non-removable pinch clamp, soft stabilization platform designed to decrease catheter movement and associated complications, and a new catheter grip design.

• Candela (Wayland, Massachusetts) said that it has received registration approval from the Brazilian National Health Surveillance Agency (ANVISA) to market the Candela Alex TriVantage multi-wavelength, q-switched laser system in Brazil. The Alex TriVantage features q-switched Laser-Pumped-Laser (LPL) technology provides 755 nm, 532 nm and 1064 nm output wavelengths. Beyond the treatment of benign pigmented lesions and the removal of multi-color tattoo inks, Alex TriVantage enhances the results of many skin rejuvenation treatments.

• CareFusion (San Diego) issued the following update regarding its previously disclosed recall of the Alaris System: On June 12, 2009, the company sent an urgent Medical Device Recall Notification to customers of its Alaris System addressing potential risks identified with the Alaris System. The affected devices have one or more failures associated with the Occlusion Warning Message, Syringe Volume Warning Message, Electrostatic Discharge protection circuitry, and Fluid Ingress into the device's pumping mechanism. This recall also updates the labeling for the Inter Unit Interface (IUI) connectors on the Alaris System. The potential risks may lead to improper infusion therapy, which could cause serious adverse health consequences or death. In addition, CareFusion today began sending customers using the Alaris Patient Controlled Analgesia (PCA) module an update to the June 12, 2009, Medical Device Recall Notification. The update contains an additional required action to mitigate potential risk before completion of the field corrective action related to the Syringe Volume Warning Message that may appear while using the Alaris PC unit with the Alaris PCA module. The additional step involves removing the patient-controlled dose request handset from the patient prior to reprogramming the infusion pump.